Supplemental Evidence and Data Request on The Effect of Dietary Digestible Carbohydrate Intake on Risk of Cardiovascular Disease, 2226-2228 [2024-00505]
Download as PDF
<![CDATA[
2226
Federal Register / Vol. 89, No. 9 / Friday, January 12, 2024 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
statutory definition of a CFI certain
advantages over non-CFI insured
depository institutions in qualifying for
Bank membership, and in the purposes
for which they may receive long-term
advances and the collateral they may
pledge to secure advances.1 Section
2(10)(A) of the Bank Act and § 1263.1 of
FHFA’s regulations define a CFI as any
Bank member the deposits of which are
insured by the Federal Deposit
Insurance Corporation and that has
average total assets below the statutory
cap.2 The Bank Act was amended in
2008 to set the statutory cap at $1
billion and to require FHFA to adjust
the cap annually to reflect the
percentage increase in the CPI–U, as
published by the DOL.3 For 2023, FHFA
set the CFI asset cap at $1,417,000,000,
which reflected a 7.1 percent increase
over 2022, based upon the increase in
the CPI–U between 2021 and 2022.4
II. The CFI Asset Cap for 2024
As of January 1, 2024, FHFA will
increase the CFI asset cap to
$1,461,000,000, which reflects a 3.1
percent increase in the unadjusted CPI–
U from November 2022 to November
2023. Consistent with the practice of
other Federal agencies required to
calculate and make annual adjustments
based on CPI–U changes, FHFA bases
the annual adjustment to the CFI asset
cap on the percentage increase in the
CPI–U from November of the year prior
to the preceding calendar year to
November of the preceding calendar
year, because the November figures
represent the most recent available data
as of January 1st of the current calendar
year. The new CFI asset cap was
obtained by applying the percentage
increase in the CPI–U to the unrounded
amount for the preceding year and
rounding to the nearest million, as has
been FHFA’s practice for all previous
adjustments.
In calculating the CFI asset cap, FHFA
uses CPI–U data that have not been
seasonally adjusted (i.e., the data have
not been adjusted to remove the
estimated effect of price changes that
normally occur at the same time and in
about the same magnitude every year).
The DOL encourages use of unadjusted
CPI–U data in applying ‘‘escalation’’
provisions such as that governing the
CFI asset cap, because the factors that
are used to seasonally adjust the data
are amended annually, and seasonally
adjusted data that are published earlier
1 See
12 U.S.C. 1424(a), 1430(a).
12 U.S.C. 1422(10)(A); 12 CFR 1263.1.
3 See 12 U.S.C. 1422(10)(B); 12 CFR 1263.1
(defining the term ‘‘CFI asset cap’’).
4 See 87 FR 80184 (Dec. 29, 2022).
2 See
VerDate Sep<11>2014
00:38 Jan 12, 2024
Jkt 262001
are subject to revision for up to five
years following their original release.
Unadjusted data are not routinely
subject to revision, and previously
published unadjusted data are only
corrected when significant calculation
errors are discovered.
Joshua R. Stallings,
Deputy Director, Division of Federal Home
Loan Bank Regulation, Federal Housing
Finance Agency.
[FR Doc. 2024–00491 Filed 1–11–24; 8:45 am]
BILLING CODE 8070–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Supplemental Evidence and Data
Request on The Effect of Dietary
Digestible Carbohydrate Intake on Risk
of Cardiovascular Disease
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Request for supplemental
evidence and data submission.
AGENCY:
The Agency for Healthcare
Research and Quality (AHRQ) is seeking
scientific information submissions from
the public. Scientific information is
being solicited to inform our review on
The Effect of Dietary Digestible
Carbohydrate Intake on Risk of
Cardiovascular Disease, which is
currently being conducted by the
AHRQ’s Evidence-based Practice
Centers (EPC) Program. Access to
published and unpublished pertinent
scientific information will improve the
quality of this review.
DATES: Submission Deadline on or
before February 12, 2024.
ADDRESSES:
Email submissions: epc@
ahrq.hhs.gov.
Print submissions:
Mailing Address: Center for Evidence
and Practice Improvement Agency for
Healthcare Research and Quality,
ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice
Improvement, Agency for Healthcare
Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers
Lane, Mail Stop 06E77D, Rockville,
MD 20857
FOR FURTHER INFORMATION CONTACT:
Kelly Carper, Telephone: 301–427–1656
or Email: epc@ahrq.hhs.gov.
SUMMARY:
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
The
Agency for Healthcare Research and
Quality has commissioned the
Evidence-based Practice Centers (EPC)
Program to complete a review of the
evidence for The Effect of Dietary
Digestible Carbohydrate Intake on Risk
of Cardiovascular Disease. AHRQ is
conducting this review pursuant to
Section 902 of the Public Health Service
Act, 42 U.S.C. 299a.
The EPC Program is dedicated to
identifying as many studies as possible
that are relevant to the questions for
each of its reviews. In order to do so, we
are supplementing the usual manual
and electronic database searches of the
literature by requesting information
from the public (e.g., details of studies
conducted). We are looking for studies
that report on The Effect of Dietary
Digestible Carbohydrate Intake on Risk
of Cardiovascular Disease.
The entire research protocol is
available online at: https://effective
healthcare.ahrq.gov/products/riskcardiovascular-disease.
This is to notify the public that the
EPC Program would find the following
information on The Effect of Dietary
Digestible Carbohydrate Intake on Risk
of Cardiovascular Disease helpful:
D A list of completed studies that
your organization has sponsored for this
topic. In the list, please indicate
whether results are available on
ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
D For completed studies that do not
have results on ClinicalTrials.gov, a
summary, including the following
elements, if relevant: study number,
study period, design, methodology,
indication and diagnosis, proper use
instructions, inclusion and exclusion
criteria, primary and secondary
outcomes, baseline characteristics,
number of patients screened/eligible/
enrolled/lost to follow-up/withdrawn/
analyzed, effectiveness/efficacy, and
safety results.
D A list of ongoing studies that your
organization has sponsored for this
topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the
trial is not registered, the protocol for
the study including, if relevant, a study
number, the study period, design,
methodology, indication and diagnosis,
proper use instructions, inclusion and
exclusion criteria, and primary and
secondary outcomes.
D Description of whether the above
studies constitute ALL Phase II and
above clinical trials sponsored by your
organization for this topic and an index
outlining the relevant information in
each submitted file.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\12JAN1.SGM
12JAN1
Federal Register / Vol. 89, No. 9 / Friday, January 12, 2024 / Notices
Your contribution is very beneficial to
the Program. Materials submitted must
be publicly available or able to be made
public. Materials that are considered
confidential; marketing materials; study
types not included in the review; or
information on topics not included in
the review cannot be used by the EPC
Program. This is a voluntary request for
information, and all costs for complying
with this request must be borne by the
submitter.
The draft of this review will be posted
on AHRQ’s EPC Program website and
available for public comment for a
period of 4 weeks. If you would like to
be notified when the draft is posted,
please sign up for the email list at:
https://www.effectivehealthcare.
ahrq.gov/email-updates.
The review will answer the following
questions. This information is provided
as background. AHRQ is not requesting
2227
that the public provide answers to these
questions.
Key Questions (KQ)
KQ 1: What is the association between
dietary digestible carbohydrate intake
and the incidence of cardiovascular
disease?
PICOTS (Populations, Interventions,
Comparators, Outcomes, Timing, and
Setting)
khammond on DSKJM1Z7X2PROD with NOTICES
INCLUSION AND EXCLUSION CRITERIA BY POPULATION, INTERVENTION, COMPARATOR, OUTCOME, TIMING, SETTING/STUDY
DESIGN (PICOTS)
PICOTS elements
Inclusion criteria
Exclusion criteria
Population ............................
• Participants who are generally healthy, including participants who are determined to be overweight/obese,
women who are pregnant or lactating.
• Age of participants:
Æ Between 2 years and 9 years (before puberty).
Æ Between 9 and 17 years.
Æ 18 years and older.
Interventions .........................
• Total dietary digestible carbohydrate intake from
foods, beverages, and dietary supplements.
Æ Total dietary digestible carbohydrate intake defined as collective starch and sugar intake; carbohydrate intake not including dietary fiber.
• A dietary pattern that quantifies the intake of total dietary digestible carbohydrates and allows the isolation of the effect of carbohydrate intake from the effect of the intake of other macronutrients.
Comparators ........................
• Different total dietary digestible carbohydrate intake
level(s).
Outcomes .............................
• Intermediate outcomes:
Æ LDL cholesterol (LDL).
Æ Total cholesterol (TC).
Æ HDL cholesterol (HDL).
Æ Non-HDL cholesterol.
Æ TC:HDL ratio.
Æ LDL:HDL ratio.
Æ Triglycerides.
Æ Blood pressure (systolic and/or diastolic) and hypertension.
• Final outcomes:
Æ Cardiovascular disease (e.g., myocardial infarction, coronary heart disease, congestive heart
failure, peripheral artery disease).
Æ Stroke.
Æ Cardiovascular disease-related mortality.
• Participants with diseases/health-related conditions
that impact carbohydrate absorption or metabolism,
cancer, and malabsorption syndromes.
• Participants hospitalized with an illness or injury.
• Participants with the endpoint outcomes of CVD (i.e.,
studies that aim to treat participants already been diagnosed with the endpoint outcomes of interest).
• Participants who intend to reduce weight or receive
treatments for being overweight and having obesity
through energy restriction or hypocaloric diets for the
purposes of treating additional or other medical conditions.
• Participants who are determined to be undernourished, underweight, stunted, or wasted.
• Participants who are pre-bariatric or post-bariatric
surgery.
• People younger than 2 years old.
• Studies that do not specify the amount of total digestible carbohydrate intake (e.g., studies that only
report type or source of digestible carbohydrate).
• Studies that do not describe the entire macronutrient
distribution of the diet (i.e., studies that do not report
total digestible carbohydrate, total fat, and total protein contents of experimental or baseline diets).
• Studies that only assess digestible carbohydrate intake via infusions (rather than the GI tract).
• Studies that primarily measure postprandial responses, as opposed to longer term studies.
• Studies that examine food products or dietary supplements not widely available to U.S. consumers.
• Multi-component interventions that do not isolate the
effect or association of digestible carbohydrate.
• Comparison of different sources of carbohydrate
without specifying amount of carbohydrate intake.
• Studies that do not attempt to control for energy intake of participants such that comparisons are made
on an isocaloric basis.
• Comparisons of available carbohydrate exposure
should not be confounded by differences in participants’ energy intake.
• Hypertensive disorders during pregnancy and/or lactation (e.g., chronic hypertension, gestational hypertension, preeclampsia-eclampsia, chronic hypertension with superimposed preeclampsia).
VerDate Sep<11>2014
00:38 Jan 12, 2024
Jkt 262001
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
E:\FR\FM\12JAN1.SGM
12JAN1
2228
Federal Register / Vol. 89, No. 9 / Friday, January 12, 2024 / Notices
INCLUSION AND EXCLUSION CRITERIA BY POPULATION, INTERVENTION, COMPARATOR, OUTCOME, TIMING, SETTING/STUDY
DESIGN (PICOTS)—Continued
PICOTS elements
Timing ..................................
Settings ................................
Study design ........................
Inclusion criteria
•
•
•
•
•
•
•
Publications ..........................
•
•
•
Exclusion criteria
At least 4 weeks ..........................................................
All except hospital and acute care ..............................
Randomized controlled trials .......................................
Nonrandomized controlled trials, including quasi-experimental and controlled before-and-after studies.
Prospective cohort studies.
Nested case-control studies.
Relevant systematic reviews, or meta-analyses (used
for identifying additional studies).
Studies published in English only ...............................
Studies published in peer-reviewed journals.
Studies published at and after the year 2000.
• Less than 4 weeks.
• Hospital and acute care.
• In vitro studies, nonoriginal data (e.g., narrative reviews, scoping reviews, editorials, letters, or erratum), retrospective cohort studies, case series, qualitative studies, cost-benefit analysis, cross-sectional
(i.e., nonlongitudinal) studies, survey.
• Non-English language studies.
Abbreviations: CVD = cardiovascular disease; GI = gastrointestinal; HDL = high-density lipoprotein; KQ = Key Question; LDL = low-density
lipoprotein PICOTS = populations, interventions, comparators, outcomes, timing, and settings; RCT = randomized controlled trial; TC = total cholesterol; U.S. = United States.
Dated: January 8, 2024.
Marquita Cullom,
Associate Director.
[FR Doc. 2024–00505 Filed 1–11–24; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission to OMB for
Review and Approval; Public Comment
Request; CAREWare Customer
Satisfaction and Usage Survey, OMB
No. 0906–xxxx–New
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
In compliance with of the
Paperwork Reduction Act of 1995,
HRSA has submitted an Information
Collection Request (ICR) to the Office of
Management and Budget (OMB) for
review and approval. Comments
submitted during the first public review
of this ICR will be provided to OMB.
OMB will accept further comments from
the public during the review and
approval period. OMB may act on
HRSA’s ICR only after the 30-day
comment period for this notice has
closed.
DATES: Comments on this ICR should be
received no later than February 12,
2024.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
00:38 Jan 12, 2024
Jkt 262001
information collection by selecting
‘‘Currently under Review—Open for
Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
request a copy of the clearance requests
submitted to OMB for review, email
Joella Roland, the HRSA Information
Collection Clearance Officer at
paperwork@hrsa.gov or call (301) 443–
3983.
SUPPLEMENTARY INFORMATION:
Information Collection Request Title:
CAREWare Customer Satisfaction and
Usage Survey, OMB No. 0906–xxxx–
New.
Abstract: HRSA developed
CAREWare, a software application first
released in 2000, to help meet the data
collection and reporting needs of Ryan
White HIV/AIDS Program (RWHAP)
grant recipients. The secure software is
a free, electronic health and social
support services information system for
RWHAP grant recipients and their
subrecipients to assist in the data
requirement submissions that inform
the development of the Ryan White
HIV/AIDS Program Service Report, the
AIDS Drug Assistance Program Data
Report, the Ending the HIV Epidemic
Initiative Triannual Report, and the
voluntary Clinical Quality Measures
Performance Measures module. Over
time, the software has evolved into a
comprehensive health information
system and is now the source of more
than half of all the RWHAP client-level
data received from recipients and
subrecipients of RWHAP grant funding.
CAREWare software manages HIV
clinical and support service data from
more than 360,000 client records in 48
states; Washington, DC; Puerto Rico;
and the U.S. Virgin Islands.
The CAREWare software application
contains customizable modules for
tracking demographic information,
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
services, medications, laboratory test
results, immunization history, diagnoses
(updated with International
Classification of Diseases, Tenth
Revision codes), referrals to outside
agencies, and an appointment
scheduler. There is a custom report
generator and a performance measures
module that supports quality of care
initiatives at the provider level. The
software also has several ways to import
data from third-party sources, including
commercial labs and other electronic
health records (using both Health Level
Seven and simple Comma Separated
Value-formatted files), HIV surveillance
systems, and for RWHAP Part B AIDS
Drug Assistance Programs, pharmacy
benefit programs. The software and user
support materials can be accessed here:
https://hab.hrsa.gov/program-grantsmanagement/careware. Finally,
CAREWare supports users through an
experienced helpdesk with ongoing
software maintenance issues and
enhancements to the user interface.
HRSA is proposing a customer
satisfaction survey to gather feedback
from CAREWare users regarding their
experiences and satisfaction with the
software platform and to obtain
suggestions for improvement.
A 60-day Federal Register Notice
(FRN) was published in the Federal
Register on October 20, 2023 (Volume
88, No. 202, pages 72493–94). There was
one out-of-scope public comment
received in response to the FRN.
Need and Proposed Use of the
Information: HRSA aims to understand
CAREWare users’ needs and concerns
by collecting information on current
software features and inquiring about
opportunities to improve the user
experience and product features. The
survey will address the software’s
functionality and how well it meets the
data collection, reporting, and quality
E:\FR\FM\12JAN1.SGM
12JAN1
]]>Agencies
[Federal Register Volume 89, Number 9 (Friday, January 12, 2024)]
[Notices]
[Pages 2226-2228]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00505]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Supplemental Evidence and Data Request on The Effect of Dietary
Digestible Carbohydrate Intake on Risk of Cardiovascular Disease
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Request for supplemental evidence and data submission.
-----------------------------------------------------------------------
SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is
seeking scientific information submissions from the public. Scientific
information is being solicited to inform our review on The Effect of
Dietary Digestible Carbohydrate Intake on Risk of Cardiovascular
Disease, which is currently being conducted by the AHRQ's Evidence-
based Practice Centers (EPC) Program. Access to published and
unpublished pertinent scientific information will improve the quality
of this review.
DATES: Submission Deadline on or before February 12, 2024.
ADDRESSES:
Email submissions: [email protected].
Print submissions:
Mailing Address: Center for Evidence and Practice Improvement Agency
for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857
Shipping Address (FedEx, UPS, etc.): Center for Evidence and Practice
Improvement, Agency for Healthcare Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD
20857
FOR FURTHER INFORMATION CONTACT: Kelly Carper, Telephone: 301-427-1656
or Email: [email protected].
SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and
Quality has commissioned the Evidence-based Practice Centers (EPC)
Program to complete a review of the evidence for The Effect of Dietary
Digestible Carbohydrate Intake on Risk of Cardiovascular Disease. AHRQ
is conducting this review pursuant to Section 902 of the Public Health
Service Act, 42 U.S.C. 299a.
The EPC Program is dedicated to identifying as many studies as
possible that are relevant to the questions for each of its reviews. In
order to do so, we are supplementing the usual manual and electronic
database searches of the literature by requesting information from the
public (e.g., details of studies conducted). We are looking for studies
that report on The Effect of Dietary Digestible Carbohydrate Intake on
Risk of Cardiovascular Disease.
The entire research protocol is available online at: https://effectivehealthcare.ahrq.gov/products/risk-cardiovascular-disease.
This is to notify the public that the EPC Program would find the
following information on The Effect of Dietary Digestible Carbohydrate
Intake on Risk of Cardiovascular Disease helpful:
[ssquf] A list of completed studies that your organization has
sponsored for this topic. In the list, please indicate whether results
are available on ClinicalTrials.gov along with the ClinicalTrials.gov
trial number.
[ssquf] For completed studies that do not have results on
ClinicalTrials.gov, a summary, including the following elements, if
relevant: study number, study period, design, methodology, indication
and diagnosis, proper use instructions, inclusion and exclusion
criteria, primary and secondary outcomes, baseline characteristics,
number of patients screened/eligible/enrolled/lost to follow-up/
withdrawn/analyzed, effectiveness/efficacy, and safety results.
[ssquf] A list of ongoing studies that your organization has
sponsored for this topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the trial is not registered, the
protocol for the study including, if relevant, a study number, the
study period, design, methodology, indication and diagnosis, proper use
instructions, inclusion and exclusion criteria, and primary and
secondary outcomes.
[ssquf] Description of whether the above studies constitute ALL
Phase II and above clinical trials sponsored by your organization for
this topic and an index outlining the relevant information in each
submitted file.
[[Page 2227]]
Your contribution is very beneficial to the Program. Materials
submitted must be publicly available or able to be made public.
Materials that are considered confidential; marketing materials; study
types not included in the review; or information on topics not included
in the review cannot be used by the EPC Program. This is a voluntary
request for information, and all costs for complying with this request
must be borne by the submitter.
The draft of this review will be posted on AHRQ's EPC Program
website and available for public comment for a period of 4 weeks. If
you would like to be notified when the draft is posted, please sign up
for the email list at: https://www.effectivehealthcare.ahrq.gov/email-updates.
The review will answer the following questions. This information is
provided as background. AHRQ is not requesting that the public provide
answers to these questions.
Key Questions (KQ)
KQ 1: What is the association between dietary digestible
carbohydrate intake and the incidence of cardiovascular disease?
PICOTS (Populations, Interventions, Comparators, Outcomes, Timing, and
Setting)
Inclusion and Exclusion Criteria by Population, Intervention,
Comparator, Outcome, Timing, Setting/Study Design (PICOTS)
------------------------------------------------------------------------
PICOTS elements Inclusion criteria Exclusion criteria
------------------------------------------------------------------------
Population..................
Participants who Participants with
are generally diseases/health-
healthy, including related conditions
participants who that impact
are determined to carbohydrate
be overweight/ absorption or
obese, women who metabolism, cancer,
are pregnant or and malabsorption
lactating. syndromes.
Age of
participants:. Participants
[cir] Between 2 hospitalized with
years and 9 years an illness or
(before puberty).. injury.
[cir] Between 9 and
17 years.. Participants with
[cir] 18 years and the endpoint
older.. outcomes of CVD
(i.e., studies that
aim to treat
participants
already been
diagnosed with the
endpoint outcomes
of interest).
Participants who
intend to reduce
weight or receive
treatments for
being overweight
and having obesity
through energy
restriction or
hypocaloric diets
for the purposes of
treating additional
or other medical
conditions.
Participants who
are determined to
be undernourished,
underweight,
stunted, or wasted.
Participants who
are pre-bariatric
or post-bariatric
surgery.
People
younger than 2
years old.
Interventions............... Total Studies
dietary digestible that do not specify
carbohydrate intake the amount of total
from foods, digestible
beverages, and carbohydrate intake
dietary supplements. (e.g., studies that
[cir] Total dietary only report type or
digestible source of
carbohydrate intake digestible
defined as carbohydrate).
collective starch Studies
and sugar intake; that do not
carbohydrate intake describe the entire
not including macronutrient
dietary fiber.. distribution of the
A dietary diet (i.e., studies
pattern that that do not report
quantifies the total digestible
intake of total carbohydrate, total
dietary digestible fat, and total
carbohydrates and protein contents of
allows the experimental or
isolation of the baseline diets).
effect of Studies
carbohydrate intake that only assess
from the effect of digestible
the intake of other carbohydrate intake
macronutrients.. via infusions
(rather than the GI
tract).
Studies
that primarily
measure
postprandial
responses, as
opposed to longer
term studies.
Studies
that examine food
products or dietary
supplements not
widely available to
U.S. consumers.
Multi-
component
interventions that
do not isolate the
effect or
association of
digestible
carbohydrate.
Comparators................. Different Comparison
total dietary of different
digestible sources of
carbohydrate intake carbohydrate
level(s). without specifying
amount of
carbohydrate
intake.
Studies
that do not attempt
to control for
energy intake of
participants such
that comparisons
are made on an
isocaloric basis.
Comparisons
of available
carbohydrate
exposure should not
be confounded by
differences in
participants'
energy intake.
Outcomes....................
Intermediate Hypertensive
outcomes: disorders during
[cir] LDL pregnancy and/or
cholesterol (LDL).. lactation (e.g.,
[cir] Total chronic
cholesterol (TC).. hypertension,
[cir] HDL gestational
cholesterol (HDL).. hypertension,
[cir] Non-HDL preeclampsia-
cholesterol.. eclampsia, chronic
[cir] TC:HDL ratio.. hypertension with
[cir] LDL:HDL ratio. superimposed
[cir] Triglycerides. preeclampsia).
[cir] Blood pressure
(systolic and/or
diastolic) and
hypertension..
Final
outcomes:
[cir] Cardiovascular
disease (e.g.,
myocardial
infarction,
coronary heart
disease, congestive
heart failure,
peripheral artery
disease)..
[cir] Stroke........
[cir] Cardiovascular
disease-related
mortality..
[[Page 2228]]
Timing...................... At least 4 Less than 4
weeks. weeks.
Settings.................... All except Hospital
hospital and acute and acute care.
care.
Study design................ Randomized In vitro
controlled trials. studies,
nonoriginal data
Nonrandomized (e.g., narrative
controlled trials, reviews, scoping
including quasi- reviews,
experimental and editorials,
controlled before- letters, or
and-after studies.. erratum),
Prospective retrospective
cohort studies.. cohort studies,
Nested case- case series,
control studies.. qualitative
Relevant studies, cost-
systematic reviews, benefit analysis,
or meta-analyses cross-sectional
(used for (i.e.,
identifying nonlongitudinal)
additional studies, survey.
studies)..
Publications................ Studies Non-English
published in language studies.
English only.
Studies
published in peer-
reviewed journals..
Studies
published at and
after the year
2000..
------------------------------------------------------------------------
Abbreviations: CVD = cardiovascular disease; GI = gastrointestinal; HDL
= high-density lipoprotein; KQ = Key Question; LDL = low-density
lipoprotein PICOTS = populations, interventions, comparators,
outcomes, timing, and settings; RCT = randomized controlled trial; TC
= total cholesterol; U.S. = United States.
Dated: January 8, 2024.
Marquita Cullom,
Associate Director.
[FR Doc. 2024-00505 Filed 1-11-24; 8:45 am]
BILLING CODE 4160-90-P
